Abstract: Myocardial ischemia is a frequent complication in patients undergoing non-cardiac surgery and b-blockers may exert a protective effect. The main benefit of b-blockers in perioperative cardiovascular morbidity and mortality is believed to be linked to specific effects on myocardial oxygen supply and demand. b-blockers may exert anti-inflammatory and anti-arrhythmic effects. Randomized clinical trials which evaluated the effects of b-blockers on all-cause mortality in patients undergoing non-cardiac surgery have yielded conflicting results. In 9 trials, 10,544 patients with non-cardiac surgery were randomized to b-blockers (n ¼ 5274) or placebo (n ¼ 5270) and there were a total of 304 deaths. Patients randomized to b-blockers group showed a 19% increased risk of all-cause mortality (odds ratio [OR] 1.19, 95% confidence interval (CI) 0.951.50; p ¼ 0.135). However, trials included in the metaanalysis differed in several aspects, and a significant degree of heterogeneity (I 2 ¼ 46.5%) was noted. A recent analysis showed that the surgical risk category had a substantial influence on the overall estimate of the effect of b-blockers. Compared with patients in the intermediatehigh-surgical-risk category, those in the high-risk category showed a 73% reduction in the risk of total mortality with b-blockers compared with placebo (OR 0.27, 95% CI 0.100.71, p ¼ 0.016). These data suggest that perioperative b-blockers confer a benefit which is mostly limited to patients undergoing high-risk surgery.
Introduction
The recent update of the 2007 joint American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) guidelines on perioperative cardiovascular (CV) evaluation and care for non-cardiac surgery [Fleischmann et al. 2009; Fleisher et al. 2007 ] recommends that b-blockers be considered in patients at high risk of heart attacks or other cardiac complications. These patients can be identified by a history of established coronary artery disease (CAD) (class IIa; level of evidence B). Similarly, b-blockers are recommended in patients who undergo intermediate-risk surgery, as well as in those with multiple risk factors for complications (e.g. diabetes, a history of heart failure (HF), significant kidney disease) who undergo vascular surgery (class IIa; level of evidence C). The recommendation remains to continue b-blockers perioperatively in patients already under treatment with these drugs (class I; level of evidence C) [Fleisher et al. 2007] (Table 1) .
Similarly, the recent guidelines of the European Society of Cardiology (ESC) for preoperative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery [Poldermans et al. 2009 ] recommend the perioperative use of b-blockers in patients with established CAD or myocardial ischemia revealed by preoperative stress testing, as well as in patients scheduled for high-risk surgery (class I; level of evidence B) ( Table 1 ).
These recommendations are based on the results of several randomized clinical trials (RCTs) which documented the cardio-protective effects of b-blockers and demonstrated a clear improvement in perioperative (30 days) and long-term (12 years) outcome in high-risk patients.
However, the results of three recent metaanalyses [Bangalore et al. 2008; Devereaux et al. 2005; Stevens et al. 2003 ] highlighted the uncertainty around the benefits from Therapeutic Advances in Cardiovascular Disease 4 (2) perioperative b-blockade. Moreover, the results of the Perioperative Ischemic Evaluation (POISE) trial [Devereaux et al. 2008] suggested that b-blockers may be harmful.
The aim of this review was to examine the potential beneficial mechanisms of b-adrenergic antagonism in perioperative medicine.
Pathophysiology of perioperative cardiac events Myocardial infarction (MI) and ischemic heart disease (IHD) are the most common causes of death during and after surgery. Patients experiencing a MI after non-cardiac surgery have an in-hospital mortality rate ranging from 15% to 25% [Kumar et al. 2001; Badner et al. 1998; Ashton et al. 1993; Shah et al. 1990] . Moreover, non-fatal perioperative MI is an independent risk factor for CV death and new non-fatal MI during the 6 months following surgery [Mangano et al. 1992] . A recent overview [Devereaux et al. 2005] of prospective cohort studies (with samples of more than 300 patients) estimated that 3.9% (95% CI 3.3%4.6%) of patients experienced major perioperative cardiac events including cardiac death, MI and cardiac arrest after non-cardiac surgery. The cause of cardiac death was attributable to MI in about 66% of the cases and to arrhythmia or HF in 34%.
Surgery may increase the risk of IHD leading to plaque rupture, thrombosis and arterial occlusion [Rosenfeld et al. 1993] . The stress of surgery (anesthesia, intubation and extubation, pain, hypothermia, bleeding and fasting) may promote an inflammatory and hypercoagulable state. Increased levels of tumor necrosis factor-a, interleukin (IL)-1, IL-6 and C-reactive protein (CRP) have been observed during surgery [Priebe, 2004; Zaugg et al. 2004] . Perioperatively, a hypercoagulable state seems to be linked to increases in plasminogen activator inhibitor-1, factor VIII and platelet reactivity, as well as decreases in antithrombin III [Flinn et al. 1984] .
Other factors which may trigger acute coronary occlusion include increased levels of catecholamines (epinephrine and norepinephrine), cortisol and an abrupt change in the sympathetic tone. Perioperative increases in catecholamine and cortisol levels contribute to increased oxygen demand and endothelial dysfunction mediated by a rise in blood pressure (BP), heart rate (HR), coronary artery shear stress, relative insulin deficiency and free fatty acid levels [Priebe, 2004] .
Another factor leading to myocardial ischemia during surgery is the hypoxic state. Bleeding and consequently anemia, hypothermia and hypoventilation due to anesthesia and analgesia may result in myocardial ischemia in the setting of hemodynamically significant coronary artery stenoses [Nelson et al. 1993] .
Autopsy studies indirectly support all of these mechanisms by showing that coronary plaque rupture and coronary thrombosis are associated with almost half of fatal postoperative MI cases [Cohen and Aretz, 1999; Dawood et al. 1996] .
Potential benefit of b-blockers in non-cardiac surgery b-blockers may protect against CV events during and after non-cardiac surgery. The primary benefit of b-blockers in perioperative CV morbidity and mortality is linked to specific effects on myocardial oxygen supply and demand [London et al. 2004] . Perioperative myocardial ischemia may be caused by an activation of the sympathetic nervous system (SNS) that increases HR, and myocardial contractility. b-blockers limit the increase in HR and myocardial contractility mediated by SNS, preventing the imbalance of myocardial oxygen supply and demand. It may be better to say that diastolic time reduces rapidly above 75 beats/min. As left ventricular coronary perfusion occurs predominantly during diastole, coronary blood flow decreases particularly distal to coronary stenoses and in the metabolically active sub-endocardium. Reducing HR directly decreases oxygen demand via reversal of the BowditchTreppe effect (e.g., increasing contractility with increasing HR) [London et al. 2004] .
However, the complexity of the interactions among the SNS, the heart, and the innate inflammatory immune response may provide other explanations for the benefit of perioperative b-blockade. b-blockers may limit activation of inflammatory responses in the myocardium and in the systemic circulation [Jenkins et al. 2002; Prabhu et al. 2000] . b-blockade directly affects leukocyte chemotaxis and recruitment, metalloproteinase activity and monocyte activation [Dunzendorfer and Wiedermann, 2000; Senzaki et al. 2000] .
Other potential effects of perioperative b-blockade have been suggested including antiarrhythmic and antirenin effects and augmentation of natriuretic peptide release [Yeager et al. 2005] . In particular, b-blockers have potent antiarrhythmic effects, especially in the setting of acute ischemia: they reduce circulating free fatty acids via inhibition of lipolysis, protecting against ventricular fibrillation and sudden cardiac death [London et al. 2004] .
Finally, b-blockers have demonstrated prophylactic properties mediated by an enhanced rate control in perioperative atrial dysrhythmias [London et al. 2004] .
Brief overview of RCTs Twenty-three clinical trials (see the appendix) evaluated the effects of b-blockers on all-cause death compared with placebo in patients undergoing non-cardiac surgery. In 14 trials no fatal events were observed while 9 trials included 10,544 patients having non-cardiac surgery and 304 deaths (see the appendix); 79% of patients recruited in these trials belong to the POISE trial [Devereaux et al. 2008] .
RCTs exploring the benefit of b-blockers in non-cardiac surgery were recently included in a systematic review [Bangalore et al. 2008] . In the 9 trials with non-zero events (see the appendix), 5274 patients were randomized to b-blockers and 5270 patients were assigned to the control group (Table 2 ). The main characteristics of the 9 trials included in the systematic review as well as the b-blockers dosage and duration in each trial are reported in Table 3 . b-blockers were not associated with a statistically significant reduction in the risk of CV mortality (OR 1.15, CI 95%: 0.851.56; p ¼ 0.358) or HF (OR 1.20, 95% CI: 0.951.52; p ¼ 0.128), but were associated with a decrease in non-fatal MI (OR 0.65, 95% CI: 0.540.79; p < 0.0001) and decrease in myocardial ischemia (OR 0.36, 95% CI: 0.260.50; p < 0.0001) at the expense of an increase in non-fatal strokes (OR 2.16, 95% CI: 1.273.68; p ¼ 0.004). One hundred and sixty-five (3.1%) and 139 (2.6%) died of any cause in the b-blocker and control groups, respectively. The ORs and 95% CI for all-cause death for each trial separately and for the combination of studies according to Peto's method are depicted in Figure 1 . Patients randomized to b-blockers showed a non-significant 19% increase in risk of all-cause death (OR 1.19, 95% CI: 0.951.50; p ¼ 0.135). However, a significant degree of statistical heterogeneity (I 2 ¼ 46.5%) was observed. The trials included in the meta-analysis, in fact, differed in many respects including the medical risk category and the risk class of the surgical procedure (Table 3 ).
The importance of high-risk The classification of surgical procedures by the ACCF/AHA guidelines for perioperative assessment of patients having non-cardiac surgery [Fleischmann et al. 2009; Fleisher et al. 2007] identified three different subgroups of surgical risk categories. Emergency and vascular surgery (aortic and other major vascular surgery including peripheral vascular surgery) were identified as high-risk category; intraperitoneal and intrathoracic surgery, carotid endarterectomy, head and neck surgery, orthopedic surgery and prostate surgery were defined as intermediate-risk surgical procedures; while cataract surgery, breast surgery, ambulatory surgery and endoscopic or superficial procedures were defined as low-risk.
A recent analysis [Angeli et al. 2009 ] and some trials [Yang et al. 2006; Poldermans et al. 1999] showed that the risk of the surgical procedure may substantially influence the protective effect of b-blockers on mortality.
Trials of patients undergoing low-and intermediate-risk surgical procedures
In the intermediatelow-surgical-risk category, b-blockers seem to have weak protective effects against major CV complications.
In a small randomized, double-blind, placebocontrolled trial, propranolol showed a nonsignificant, but clinically relevant, 70% relative risk reduction in the rate of treated arrhythmias (p ¼ 0.071) [Bayliff et al. 1999] . However, a slight increase in all-cause death was documented in the propranolol group.
In the Beta Blocker in Spinal Anesthesia (BBSA) trial [Zaugg et al. 1999] , the effect of bisoprolol was compared with that of placebo on 1-year follow-up in patients undergoing surgery with spinal block at intermediatelow risk. The incidence of all-cause death was identical between treatment groups (OR 1.00, 95% CI: 0.0616.09).
The POISE trial [Devereaux et al. 2008 ] is the largest placebo-controlled trial of perioperative b-blocker use. A total of 8351 patients were randomized to receive extended-release metoprolol succinate or placebo, starting just before surgery and continuing for the subsequent 30 days. In the POISE trial, 2425 patients (58.1%) in the metoprolol group and 2461 patients (58.9%) in the control group underwent intermediatelow-risk surgical procedures. The primary end-point was a composite of CV death, non-fatal MI and non-fatal cardiac arrest. At 30 days, the incidence Table 3 . b-blocker dose and duration of treatment in randomized clinical trials which evaluated the effects of these drugs on all-cause death compared with placebo in patients undergoing non-cardiac surgery. of the primary end-point was lower in the metoprolol group than in the placebo group (5.8% vs. 6.9%, hazard ratio 0.83; p ¼ 0.04) but more patients randomized to metoprolol died of any cause (3.1% vs. 2.3%; p ¼ 0.03).
Trials of patients undergoing high-risk surgical procedures
In trials performed in high-risk surgical procedures, a clear benefit of b-blockers on all-cause mortality was observed.
A remarkable protective effect of perioperative b-blockers on mortality was observed in patients having vascular surgery [Poldermans et al. 1999 ].
Poldermans and co-workers showed that patients receiving bisoprolol had a significant 78% risk reduction of all-cause death compared with patients randomized to placebo.
In the Metoprolol after Vascular Surgery (MaVS) trial [Yang et al. 2006] , patients having vascular surgery were randomized to metoprolol or placebo. During follow-up, a lower incidence of all-cause death was observed in the metoprolol group (0.4%) than in the placebo group (2.8%).
The favorable prognostic impact of b-blockers in patients having high-risk surgical procedures is strongly supported by a recent analysis from our group [Angeli et al. 2009 ]. We performed a meta-regression analysis using the different surgical risk categories as covariate to explain the significant degree of statistical heterogeneity (I 2 ¼ 46.5%) observed across the trials included in the meta-analysis of Bangalore and co-workers [Bangalore et al. 2008] .
We found that the overall heterogeneity in the effect of b-blockers on total mortality across the trials was entirely accounted for by the differing surgical risk (I 2 ¼ 0). Compared with patients in the intermediatehigh-risk category, those in the high-risk category showed a remarkable 73% reduction in the risk of total mortality with b-blockers compared with placebo (OR 0.27, 95% CI 0.100.71, p ¼ 0.016). When the trials with no events in either arm see the Appendix were included (statistical technique of continuity correction), the estimate did not change (OR 0.27; 95% CI 0.110.74; p ¼ 0.013) . No differences were found between the intermediate-and intermediatehigh-risk categories before (OR 1.12; 95% CI: 0.1210.40; p ¼ 0.90) and after (OR 1.09; 95% CI: 1.167.48; p ¼ 0.92) continuity correction.
We also performed a Monte Carlo permutation test to determine the 'true' statistical significance of a positive finding in our meta-regression [Angeli et al. 2009] . Using this method, the p-value of the estimates for the high-risk category, after 10,000 random permutations, was 0.017 (for the Peto's OR, 9 trials) and 0.0159 (for continuity corrected OR, 23 trials). The p-values after correction for multiple testing were 0.040 and 0.0306 for the Peto's OR and the continuity corrected OR, respectively.
Clinical implications
The possible mechanisms for increased mortality with b-blockers in non-cardiac surgery are not understood. In the POISE trial [Devereaux et al. 2008] , the major contributor to the higher mortality rate in the metoprolol group was sepsis. However, the mechanisms through which b-blockers may predispose to sepsis are still unclear. Two possible speculative explanations were offered by the authors: b-blockers could predispose to sepsis by the possible induced hypotension and b-blockers could mask normal responses to systemic infection by reducing heart rate.
In addition, the POISE trial [Devereaux et al. 2008 ] is under scrutiny for its dosing regimen (extended release metoprolol succinate 100 mg or placebo 24 hours before surgery; another 100 mg or placebo 6 hours after surgery; 200 mg or placebo 12 hours after the second dose and every 24 hours thereafter for 30 days). This treatment protocol (Table 3 ) was fairly aggressive, especially for older patients who had never received a b-blocker in the past. Presumably, it could promote hemodynamic instability and hypotension, especially in patients with left ventricular dysfunction. The risk of clinically significant hypotension was, indeed, substantially higher in the metoprolol group when compared with the control group (hazard ratio 1.55, 95% CI: 1.381.74, p < 0.0001). Moreover, the association between clinically significant hypotension and risk of all-cause death observed in the POISE trial (OR 4.97, 95% CI: 3.626.81) may explain the increased risk of death in the metoprolol group.
Another criticism is that the medication was started only a few hours before surgery.
However, results of other clinical trials in subjects having intermediate-or low-risk surgical procedures showed that b-blockers are poorly effective in preventing all-cause death. Surgical-risk category appears to be fundamental to explaining the variable effect of b-blockers on total mortality in patients undergoing non-cardiac surgery. In a previous meta-regression analysis from our group, a remarkable 73% lower risk of total mortality with b-blockers than with placebo (odds ratio 0.27, 95% CI 0.100.71; p ¼ 0.016) was observed in patients in the high-risk category compared with patients in the intermediate-risk category [Angeli et al. 2009] . Results of our analysis suggest that patients having high-risk surgery according to the ACCF/AHA guidelines for perioperative assessment of patients having non-cardiac surgery [Fleischmann et al. 2009; Fleisher et al. 2007] are probably the ideal target population for the use of perioperative b-blockers.
However, some other aspects of perioperative b-blockers remain unaddressed as suggested by the recent updates of ESC and ACCF/AHA guidelines [Fleischmann et al. 2009; Poldermans et al. 2009] . It is unclear whether the potential benefit of b-blockers in these patients is a class effect equally valid for all agents, and the association between duration of b-blockers therapy after surgery and risk of major CV events is still controversial.
Moreover, the potential side effects of the therapy should be evaluated carefully; physicians must be vigilant when b-blockers are started in patients not yet taking these drugs and the medication should be probably initiated well before the procedure and titrated-up on the basis of blood pressure and heart rate [Fleischmann et al. 2009; Fleisher et al. 2007] . Properly designed clinical trials are needed to determine the most appropriate timing for starting treatment with b-blockers before surgery and the duration of therapy after the surgical procedure.
In conclusion, differences in patient characteristics, type of surgery and administration of b-blockers may explain the different protective effects observed in clinical trials.
The perioperative use of b-blockers is recommended in high-risk surgery (class I; level of evidence B) and may be encouraged in intermediate-risk surgery (Class IIa, Level of evidence B).
Moreover, according to recent guidelines [Fleischmann et al. 2009; Poldermans et al. 2009 ], treatment with b-blockers should be initiated between 30 days and 1 week before surgery with a target resting heart rate 6070 beats/ min and systolic blood pressure >100 mmHg. Postoperative tachycardia requires, first of all, diagnosis and management of potential underlying causes (i.e., hypovolemia, hemorrhages, infections) before considering up-titration of b-blocker dosage.
